Close Menu

mergers & acquisitions

Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.

EdiGene has developed a diploid library of 2,800 single clonal knockout cell lines, targeting 2,600 genes in commonly used human cancer cell lines.

Invitae sees Jungla's AI platform as complementary to its own variant classification and interpretation methods.

The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.

Vermont-based BioTek is a privately held company that manufactures and sells life science instruments, including cell imaging systems.

As expected, the UK's Competition and Markets Authority is referring the proposed Illumina acquisition of PacBio for an in-depth Phase 2 investigation.

Transplant Genomics offers a test that assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection.

The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.

Bratislava-based HighChem offers software that is used by pharmaceutical and metabolomics laboratories for analyzing complex data and identifying small molecules.

Cytobank provides a cloud- and machine learning-based software platform for multi-parametric single-cell data analysis, sharing, and archiving.

Pages

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.